Par Drugs and Chemicals Limited

Par Drugs and Chemicals Limited

Par Drugs and Chemicals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming dematerialisation of securities and listing on stock exchanges.

Par Drugs and Chemicals Limited

Par Drugs and Chemicals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will remain closed from Thursday, October 1, 2026, till the expiry of 48 hours after the declaration of unaudited standalone financial results for the quarter and half year ended on September 30, 2026.

Par Drugs and Chemicals Limited

Par Drugs and Chemicals Limited has submitted the Exchange a copy Scrutinizer report of Annual General Meeting held on September 26, 2026. The company has informed the Exchange regarding voting results.

Par Drugs and Chemicals Limited

Par Drugs and Chemicals Limited held its 27th Annual General Meeting on September 26, 2026, at Hotel Tara Suns in Vadodara. The meeting was chaired by Mr. Falgun V. Savani, Chairman and Managing Director. The company reported a total income of ₹107.66 crore in FY 2025-26, with a profit before tax of ₹17.30 crore and a profit after tax of ₹13.11 crore. The company remained debt-free throughout the year and closed FY 2025-26 with cash and cash equivalents of approximately ₹41.84 crore.

Par Drugs and Chemicals Limited

Par Drugs and Chemicals Limited held its 27th Annual General Meeting on September 26, 2026, where the Chairman and Managing Director, Mr. Falgun V. Savani, briefed the shareholders on the company's financial performance for FY 2025-26, which reported a total income of ₹107.66 crore, profit before tax of ₹17.30 crore, and profit after tax of ₹13.11 crore. The company remained debt-free and had a cash and cash equivalents of approximately ₹41.84 crore.

Par Drugs and Chemicals Limited

Par Drugs and Chemicals Limited has informed the Exchange about a copy of newspaper publication regarding AGM Notice and e-voting information for the 27th Annual General Meeting of the Company.

Par Drugs and Chemicals Limited

Par Drugs and Chemicals Limited has informed the Exchange regarding 'Regulation 36 (1)(b)' and sent letters to members whose email addresses are not registered with the Company/Registrar & Share Transfer Agent/Depository Participants, providing the web-link to access the Annual Report for FY 2025-26 and the Notice convening the 27th Annual General Meeting of the Company.

Par Drugs and Chemicals Limited

Par Drugs and Chemicals Limited has announced the 27th Annual General Meeting (AGM) to be held on September 26, 2026, at Hotel Tara Suns in Vadodara, Gujarat. The meeting will consider the audited standalone financial statements for the financial year ended March 31, 2026, and other business items.

Par Drugs and Chemicals Limited

Par Drugs and Chemicals Limited has announced the outcome of its Board Meeting held on August 22, 2026. The Board has decided on various matters including the 27th AGM, remuneration for directors, and the appointment of statutory and internal auditors.

Par Drugs and Chemicals Limited

Par Drugs And Chemicals Limited has informed the Exchange regarding the appointment of M/s Maulin Shah & Associates, Cost Accountant as Cost Auditor of the Company w.e.f. April 01, 2026. The company also approved various resolutions including the re-appointment of directors, increase in remuneration of certain directors, and appointment of statutory and internal auditors.

Par Drugs and Chemicals Limited

Par Drugs and Chemicals Limited has informed the Exchange regarding the appointment of Ms SIDDHPURA & CO as Internal Auditor of the company w.e.f. April 01, 2026. The Board also approved the appointment of Statutory Auditor M/s. Sarupria Somani & Associates, Chartered Accountants, for the FY 2026-27, and re-appointed M/s. SIDDHPURA & CO as Internal Auditor of the Company for the FY 2026-27. The Board also approved the re-appointment of Mr. Jignesh Vallabhbhai Savani as Director & CEO, and the increase in remuneration of Mr. Jignesh Vallabhbhai Savani, Mr. Falgun Vallabhbhai Savani, and Mr. Pravin Manjibhai Bhayani.

Par Drugs and Chemicals Limited

Par Drugs And Chemicals Limited has informed the Exchange regarding 'Outcome of Board Meeting dated 22.08.2026'. The meeting of Board of Directors of the Company held on Saturday, 22nd day of August, 2026 at 4:00 PM through Video Conferencing mode, transacted the following businesses: approval of Notice of the 27th AGM, relevant dates for the ensuing 27th Annual General Meeting, Secretarial Audit Report, Directors Report, re-appointment of Mr. Jignesh Vallabhbhai Savani as Director & CEO, increase in remuneration of Mr. Falgun Vallabhbhai Savani and Mr. Jignesh Vallabhbhai Savani, appointment of M/s. Sarupria Somani & Associates as Statutory Auditor, and re-appointment of M/s. SIDDHPURA & CO as Internal Auditor.

Par Drugs and Chemicals Limited

Par Drugs and Chemicals Limited has informed the Exchange about the publication of a notice to shareholders whose shares are liable to be transferred to the Investor Education and Protection Fund (IEPF) due to unclaimed dividends.

Par Drugs and Chemicals Limited

Par Drugs and Chemicals Limited has informed the Exchange about the submission of newspaper cuttings regarding standalone unaudited financial results for the quarter ended June 30, 2026.

Par Drugs and Chemicals Limited

Par Drugs and Chemicals Limited has informed the Exchange regarding 'Outcome of Board Meeting dated 08.08.2026'. The meeting of Board of Directors considered and approved the Unaudited Standalone Financial Results of the Company for the quarter ended on 30th June, 2026. The Board also approved the drafts of advertisements to be published in newspapers regarding the Unaudited Standalone Financial Results. Additionally, the Board took note of Investor grievances report and reviewed the SCORES platform of SEBI to solve the investor compliant till date. The Board also approved the Corporate Governance Report of the Company for the quarter ended 30th June, 2026. Furthermore, the Board considered and approved the Policy on Communication between Statutory Auditor and Those Charged with Governance (TCWG).

Par Drugs and Chemicals Limited

Par Drugs and Chemicals Limited has informed the Exchange regarding Outcome of Board Meeting held on August 08, 2026. The meeting of Board of Directors of the Company considered, approved and took on record the Unaudited Standalone Financial Results of the Company for the quarter ended on 30th June, 2026 along with Limited Review Report given CA Mira! Mehta, Partner of Sarupria Somani & Associates, Chartered Accountants, Statutory Auditor of the Company. The Board also considered and approved the drafts of advertisements to be published in newspapers regarding Unaudited Standalone Financial Results of the Company for the quarter ended on 30th June, 2026.

Par Drugs and Chemicals Limited

Par Drugs and Chemicals Limited has announced its unaudited standalone financial results for the quarter ended June 30, 2026, and has approved the same at its board meeting. The company has also approved various other matters, including availing forward booking banking facilities, appointing a portfolio manager, and purchasing new motor vehicles for its directors.

Par Drugs and Chemicals Limited

Par Drugs and Chemicals Limited has informed the National Stock Exchange of India Limited about a Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026.

Par Drugs and Chemicals Limited

Par Drugs and Chemicals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.